Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Galectin-3 Expression is a Potent Prognostic Marker in Colorectal Cancer

KAZUYA ENDO, SHUNJI KOHNOE, EIJI TSUJITA, AKIHIRO WATANABE, HIDEAKI NAKASHIMA, HIDEO BABA and YOSHIHIKO MAEHARA
Anticancer Research July 2005, 25 (4) 3117-3121;
KAZUYA ENDO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kendo@munakata-med-hp.gr.jp
SHUNJI KOHNOE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EIJI TSUJITA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AKIHIRO WATANABE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEAKI NAKASHIMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEO BABA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIHIKO MAEHARA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Galectin-3 is a β-galactoside-binding protein whose expression has been correlated with progression and metastasis in colon cancer. It is expressed at elevated levels in a variety of neoplastic cells. The current study was designed to investigate, by clinicopathological analysis, the relationship between prognosis and galectin-3 expression, in colorectal cancer. Patients and Methods: Galectin-3 expression was evaluated using immunohistochemical staining in 121 consecutive patients with colorectal cancer. The relationship between galectin-3 expression and clinicopathological factors was analyzed. Results: Galectin-3-positive expression was detected in 79 patients (65%). The incidence of lymph node and distant metastasis in galectin 3-positive cancer was significantly higher than that in galectin-3-negative cases (p=0.0007 and p=0.014, respectively). Furthermore, cancers with galectin-3-positive expression revealed frequent venous invasion (p=0.005) and lymphatic permeation(p=0.041), larger size (p=0.016) and deeper invasion to wall(p=0.01) than in galectin-3-negative cases. While univariate analysis showed that survival in patients with galectin-3-positive expression was significantly poorer than in galectin-3-negative cases (p=0.0027), galectin-3 expression was a prognostic factor independent of Dukes' stage and lymph node metastasis by multivariate analysis. Conclusion: We propose that galectin-3 expression is an independent factor for prognosis in colorectal cancer.

  • Colorectal cancer
  • galectin-3 expression
  • prognosis
  • immunohistochemistry

Footnotes

  • Received January 18, 2005.
  • Accepted May 12, 2005.
  • Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 25 (4)
Anticancer Research
Vol. 25, Issue 4
1 Jul 2005
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Galectin-3 Expression is a Potent Prognostic Marker in Colorectal Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Galectin-3 Expression is a Potent Prognostic Marker in Colorectal Cancer
KAZUYA ENDO, SHUNJI KOHNOE, EIJI TSUJITA, AKIHIRO WATANABE, HIDEAKI NAKASHIMA, HIDEO BABA, YOSHIHIKO MAEHARA
Anticancer Research Jul 2005, 25 (4) 3117-3121;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Galectin-3 Expression is a Potent Prognostic Marker in Colorectal Cancer
KAZUYA ENDO, SHUNJI KOHNOE, EIJI TSUJITA, AKIHIRO WATANABE, HIDEAKI NAKASHIMA, HIDEO BABA, YOSHIHIKO MAEHARA
Anticancer Research Jul 2005, 25 (4) 3117-3121;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • The Growing Galectin Network in Colon Cancer and Clinical Relevance of Cytoplasmic Galectin-3 Reactivity
  • Google Scholar

More in this TOC Section

  • Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
  • Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
  • Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire